PFIZER INC (PFE): restructuring charge — Pfizer launches multi-year COGS reduction program; targets $1.5B savings by 2027

PFIZER INC

First phase of cost-reduction program expected to deliver ~$1.5B savings by end of 2027.
One-time costs estimated at ~$1.7B, primarily severance and implementation costs.
Costs recorded mostly in 2024; cash outlays expected in 2025 and 2026.
Program includes operational efficiencies, network structure changes, and portfolio enhancements.
Savings realization expected to begin in 2025.

item 2.05

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

PFIZER INC announced a restructuring with charges of approximately $1.7 billion affecting cost of goods sold.

Type: restructuring
Charge: approximately $1.7 billion
Affected area: cost of goods sold

Exact text from the filing

of which is expected to begin being realized in 2025. The one-time costs to achieve the savings associated with the first phase of the program are expected to be approximately $1.7 billion and primarily include severance and implementation costs. These costs will be recorded primarily in 2024, with cash outlays expected in 2025 and 2026. The estimate of costs that

View on SEC.gov

Browse all restructurings & charges →

PFIZER INC filing history →

Source: SEC EDGAR

accession 0000078003-24-000113

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.